ULTRAGENYX PHARMACEUTICAL
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.
ULTRAGENYX PHARMACEUTICAL
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2010-01-01
Address:
Novato, California, United States
Country:
United States
Website Url:
http://www.ultragenyx.com
Total Employee:
501+
Status:
Active
Contact:
+1 415 483 8800
Email Addresses:
[email protected]
Total Funding:
185 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon Google Tag Manager WordPress Sitelinks Search Box Euro Amazon Yoast WordPress SEO Plugin Yoast SEO Premium
Similar Organizations
AcelRx Pharmaceuticals
AcelRx Pharmaceuticals focuses on the development and commercialization of therapies for the treatment of pain and other conditions.
Alexza Pharmaceuticals
Alexza Pharmaceuticals is a pharmaceutical company developing novel products for the treatment of acute and intermittent conditions.
Anthera Pharmaceuticals
Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Apexigen
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics.
Aradigm
Aradigm is a pharmaceutical company focused on the development of drugs for the treatment of severe respiratory diseases.
Cellix Bio
Cellix Bio provides medical research services to develop drug products for the treatment of immune and other related diseases.
EnBiotix
EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Eolo Pharma
Eolo Pharma focuses on developing drugs targeting the molecular and cellular basis of inflammation-related diseases
Forendo Pharma
Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Imricor Medical Systems
Imricor Medical Systems develops magnetic resonance imaging compatible electrophysiology tools for the treatment of cardiac arrhythmias.
Innovus Pharmaceuticals
Innovus Pharmaceuticals develops healthcare products for dermatology, autoimmune, respiratory, and sexual dysfunction diseases.
IntelGenX
IntelGenX is an oral drug delivery company primarily that focuses on the development and manufacturing of pharmaceutical oral films.
Karuna Therapeutics
Karuna Therapeutics is a Massachusetts-based developer of drugs for the treatment of schizophrenia.
Melt Pharmaceuticals
Melt Pharmaceuticals focuses on developing novel approach to providing procedural sedation and analgesia for short-term medical procedures.
Mithra Pharmaceuticals SA
Mithra Pharmaceuticals SA specializes in the development of women's health care products.
MusclePharm
MusclePharm provides sports nutrition products and supplements for athletes of all kinds.
Neurana Pharmaceuticals
Neurana Pharmaceuticals is currently developing a novel treatment for acute muscle spasms.
Orphion Therapeutics
Orphion Therapeutics is focused on the development of novel gene therapies for the treatment of rare and serious genetic disorders.
PBS Biotech
PBS Biotech is produces the easiest to use and most technologically-advanced bioreactors for the pharmaceutical industry.
Santhera Pharmaceuticals
Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.
Synerkine Pharma
Synerkine Pharma is a developer of fusion proteins for the treatment of chronic pain.
TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals discovers and develops small molecule drugs for the treatment of debilitating diseases and conditions.
Waterstone Pharmaceuticals
Waterstone Pharmaceuticals is engaged in the development of various drugs for the treatment of liver and gastrointestinal diseases.
Westlake Therapeutics
The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.
ZS Pharma
ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-07-18 | GeneTx Biotherapeutics | GeneTx Biotherapeutics acquired by Ultragenyx Pharmaceutical | 75 M USD |
| 2017-09-18 | Dimension Therapeutics | Dimension Therapeutics acquired by Ultragenyx Pharmaceutical | 152.3 M USD |
Investors List
Takeda Ventures
Takeda Ventures investment in Post-IPO Equity - Ultragenyx Pharmaceutical
Takeda
Takeda investment in Post-IPO Equity - Ultragenyx Pharmaceutical
F-Prime Capital
F-Prime Capital investment in Series B - Ultragenyx Pharmaceutical
Adage Capital Management
Adage Capital Management investment in Series B - Ultragenyx Pharmaceutical
HealthCap
HealthCap investment in Series B - Ultragenyx Pharmaceutical
Pappas Ventures
Pappas Ventures investment in Series B - Ultragenyx Pharmaceutical
TPG Growth
TPG Growth investment in Series B - Ultragenyx Pharmaceutical
BlackRock Private Equity Partners
BlackRock Private Equity Partners investment in Series B - Ultragenyx Pharmaceutical
HealthCap
HealthCap investment in Series A - Ultragenyx Pharmaceutical
F-Prime Capital
F-Prime Capital investment in Series A - Ultragenyx Pharmaceutical
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-10-23 | Solid Biosciences | Ultragenyx Pharmaceutical investment in Post-IPO Equity - Solid Biosciences | 40 M USD |
Newest Events participated
Official Site Inspections
http://www.ultragenyx.com Semrush global rank: 921.99 K Semrush visits lastest month: 39.3 K
- Host name: 104.18.27.199
- IP address: 104.18.27.199
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
